Literature DB >> 14695993

Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation.

Enric Domingo1, Eloi Espín, Manel Armengol, Carla Oliveira, Mafalda Pinto, Alex Duval, Caroline Brennetot, Raquel Seruca, Richard Hamelin, Hiroyuki Yamamoto, Simó Schwartz.   

Abstract

BRAF, a serine/threonine kinase of the RAF family, is a downstream transducer of the RAS-regulated MAPK pathway and signals upstream of MEK1/2 kinases. Recently, activating mutations within BRAF have been reported in a high percentage of melanomas and colorectal carcinomas and shown to have oncogenic capabilities. Further, their association to mismatch-repair-deficient tumors has suggested the involvement of the RAS/RAF pathway in the tumorigenesis of microsatellite-unstable colon cancers, and that RAS and RAF mutations are alternative genetic events. We determined whether colorectal mismatch-repair-deficient tumors with BRAF mutations show a specific genotype when compared with tumors with wild-type BRAF, and whether they can be associated with a particular clinicopathological feature. Here, we report a striking association of BRAF, but not of APC, KRAS2, AXIN2, and TP53 mutations, with proximal mismatch-repair-deficient colon tumors and MLH1 hypermethylation. Our results support the hypothesis that proximal and distal colorectal tumors with mismatch repair deficiency harbor different genetic alterations, and we suggest that the involvement of the RAS/RAF pathway in colorectal tumorigenesis is differentially modulated according to tumor location and MLH1 inactivation. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695993     DOI: 10.1002/gcc.10310

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  30 in total

1.  B-Raf mutations, microsatellite instability and p53 protein expression in sporadic basal cell carcinomas.

Authors:  Angeliki Stamatelli; Angelica A Saetta; Thaleia Bei; Nicolaos Kavantzas; Nicolaos V Michalopoulos; Efstratios Patsouris; Kiriaki Aroni
Journal:  Pathol Oncol Res       Date:  2011-01-28       Impact factor: 3.201

2.  MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.

Authors:  Mireia Gausachs; Pilar Mur; Julieta Corral; Marta Pineda; Sara González; Llúcia Benito; Mireia Menéndez; Josep Alfons Espinàs; Joan Brunet; María Dolores Iniesta; Stephen B Gruber; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

3.  Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.

Authors:  Hanifa Bouzourene; Pierre Hutter; Lorena Losi; Patricia Martin; Jean Benhattar
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 4.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

5.  The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.

Authors:  Shan Muhammad; Zheng Jiang; Zheng Liu; Kavanjit Kaur; Xishan Wang
Journal:  J Gastrointest Oncol       Date:  2013-03

Review 6.  Diversity of axin in signaling pathways and its relation to colorectal cancer.

Authors:  Nighat Parveen; Mahboob Ul Hussain; Arshad A Pandith; Syed Mudassar
Journal:  Med Oncol       Date:  2010-10-30       Impact factor: 3.064

Review 7.  Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms.

Authors:  Laura Novellasdemunt; Pedro Antas; Vivian S W Li
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-19       Impact factor: 4.249

8.  Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin.

Authors:  Manuela Pinheiro; Terje Ahlquist; Stine A Danielsen; Guro E Lind; Isabel Veiga; Carla Pinto; Vera Costa; Luís Afonso; Olga Sousa; Maria Fragoso; Lúcio Santos; Rui Henrique; Paula Lopes; Carlos Lopes; Ragnhild A Lothe; Manuel R Teixeira
Journal:  BMC Cancer       Date:  2010-10-27       Impact factor: 4.430

9.  A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation.

Authors:  Ana Preto; Cátia Moutinho; Sérgia Velho; Carla Oliveira; Ana Paula Rebocho; Joana Figueiredo; Paula Soares; José Manuel Lopes; Raquel Seruca
Journal:  Virchows Arch       Date:  2007-05-09       Impact factor: 4.064

10.  Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.

Authors:  Sérgia Velho; Carla Oliveira; Joana Paredes; Sónia Sousa; Marina Leite; Paulo Matos; Fernanda Milanezi; Ana Sofia Ribeiro; Nuno Mendes; Danilo Licastro; Auli Karhu; Maria José Oliveira; Marjolijn Ligtenberg; Richard Hamelin; Fátima Carneiro; Annika Lindblom; Paivi Peltomaki; Sérgio Castedo; Simó Schwartz; Peter Jordan; Lauri A Aaltonen; Robert M W Hofstra; Gianpaolo Suriano; Elia Stupka; Arsenio M Fialho; Raquel Seruca
Journal:  Hum Mol Genet       Date:  2009-12-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.